

1 **Microbiota-derived PPAR- γ signaling and risk of bacterial enteric infection:**
2 **insight from thiazolidinedione users in a US population-based study**

3 Morgan Birabaharan^{1*}, David C Kaelber², Victor Nizet³⁻⁴, Amir Zarrinpar^{5-9*}

4 1 Division of Infectious Diseases and Global Public Health, University of California, San Diego,
5 La Jolla, California, USA

6 2 Departments of Population and Quantitative Health Sciences, Case Western Reserve
7 University School of Medicine, Cleveland, Ohio, USA

8 3 Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, UC San Diego
9 School of Medicine

10 4 Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, LA Jolla,
11 California

12 5 Division of Gastroenterology, University of California, San Diego, La Jolla, CA, USA

13 6 Center for Microbiome Innovation, University of California, San Diego, La Jolla, CA, USA.

14 7 Division of Gastroenterology, Jennifer Moreno Department of Veterans Affairs Medical Center

15 8 Institute of Diabetes and Metabolic Health, University of California, San Diego, La Jolla, CA,
16 USA

17 9 Shu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La
18 Jolla, CA, USA

19

20 *co-Corresponding author

21 Lead Contact: Amir Zarrinpar, MD, PhD, 9500 Gilman Dr, MC 0983, University of California, San
22 Diego, La Jolla, CA 92093-0983

23

24

25

26

27

28

29

30

31

32 **Abstract**

33 The ongoing antimicrobial resistant crisis heralds the need for new therapeutics against enteric
34 infection. In mouse models, colon epithelial peroxisome proliferator-activated receptor- γ (PPAR-
35 γ) signaling limits oxygen and nitrate luminal bioavailability, thereby preventing bacterial
36 pathogen colonization. However, whether this mechanism operates similarly in humans remains
37 uncertain. To investigate, we used the cloud-based TriNetX Analytics Platform which aggregates
38 health records from 117 million patients across 66 US healthcare organizations, to assess the
39 risk of bacterial enteric infection among diabetic patients prescribed thiazolidinediones, a class
40 of PPAR- γ agonists. Among 85,117 thiazolidinedione users, we observed a 22-49% lower risk of
41 bacterial enteric infections compared to users of other anti-diabetes medications. This reduction
42 in risk was consistent across high-risk individuals, regardless of sex or age. Similar results were
43 replicated in high-risk patients when thiazolidinedione users were directly compared to those on
44 DPP-4 inhibitors. These findings support the potential protective role of PPAR- γ signaling
45 against bacterial enteric infection and call for further clinical investigation.

46

47 **Introduction**

48 The body's primary defense against bacterial enteric infection relies heavily on the abundant
49 and diverse intestinal microbiota [1,2]. These gut commensal microbes confer protection by
50 direct bacteria-to-bacteria interactions and activating host immune defenses—a phenomenon
51 known as colonization resistance [1,2]. Amid the ongoing antimicrobial resistant crisis,
52 understanding the mechanisms of colonization resistance has gained increasing importance.
53 Identifying microbial metabolites, proteins, or host receptors involved in preventing infection can
54 lead to new anti-infective strategies and potentially reduce the 1.6-2.1 million annual diarrheal
55 deaths worldwide [3].

56 Recent mechanistic studies have highlighted a central role of the host nuclear hormone receptor
57 peroxisome proliferator-activated receptor (PPAR- γ) in colonization resistance [4,5]. Commensal
58 colonic microbes, predominantly obligate anaerobes, thrive in an oxygen- and nitrate- deprived
59 environment, limiting the expansion of facultative anaerobic organisms such as *Salmonella* and
60 Enterobacteriaceae. These microbes maintain the low-oxygen environment by producing
61 metabolites such as butyrate, which activates PPAR- γ in colonocytes [4,5]. This activation
62 enhances oxygen consumption by the host, sustaining the protective anaerobic state. In mouse
63 models, depletion of PPAR- γ signaling—triggered by antibiotics or a high-fat diet—has been
64 associated with increased bacterial pathogenesis, aligning with well-known patient risk factors
65 [4-9]. Pharmacological PPAR- γ agonists have also shown promising results in restoring this
66 protective effect [10]. However, it remains unclear whether PPAR- γ offers similar protection
67 against enteric infection in humans.

68 Thiazolidinediones, a class of PPAR- γ agonists, are commonly used in the management of type
69 2 diabetes mellitus (T2DM) [11,12]. Assessing the risk of bacterial enteric infection in
70 thiazolidinediones users compared to those receiving other anti-diabetes medications could
71 provide insights into the viability of targeting PPAR- γ for anti-infective purposes. In this study, we
72 conducted a population-based analysis in the US to assess the risk of bacterial enteric infection
73 in T2DM patients using thiazolidinediones anti-diabetes medications.

74

75 **Methods**

76 **Data**

77 We used the cloud-based TriNetX Analytics Platform, US Collaborative Network, to obtain web-
78 based real-time secure access to fully deidentified electronic health records of 117 million
79 patients from 66 health care organizations, representing 27% of the US population from all 50

80 states. Both inpatient and outpatient settings mostly from large academic medical institutions in
81 the US, as well as persons from diverse geographic, age, race and ethnicity, income, and
82 insurance groups are represented. The geographic distribution of patients from the TriNetX
83 platform is 25% in the Northeast, 17% in the Midwest, 41% in the South, and 12% in the West,
84 with 5% unknown.

85

86 **Ethics Statement**

87 The TriNetX platform aggregates and HIPAA de-identifies data contributed from the electronic
88 health records of participating healthcare organizations. The TriNetX platform also only reports
89 population-level results (no access to individual patient data) and uses statistical blurring,
90 reporting all population-level counts between 1 and 10 as 10. Because this study used only
91 deidentified patient records, it was exempted from review by the MetroHealth System
92 Institutional Review Board.

93

94 **Study populations**

95 Risk for bacterial enteric infection can often be based on factors that are not well captured by
96 electronic medical records, including consumption of undercooked meat or international travel,
97 and may be a rare occurrence in those without risk factors present. Therefore, the outcome of
98 bacterial enteric infection after prescription of thiazolidinedione or other anti-diabetes medication
99 was determined among a “low-risk” and “high-risk” cohort. Low-risk for bacterial enteric infection
100 was defined as no prior history of bacterial enteric infection. High-risk was defined as persons
101 with a previous diagnosis of bacterial enteric infection, suggesting risk factors for disease such
102 as altered gut microbiota, behavioral and environmental factors, or predisposing chronic
103 diseases are present [13-16].

104

105 The study was designed for a 5-year recruitment date, from 3 January 2017 to an end date of 3
106 January 2022. The start date was chosen to help include the approval of semaglutide for T2DM
107 management (FDA approved Dec 2017) and the end date was chosen to minimize overlap of
108 GLP1 agonist approval for weight loss in those without diabetes (FDA approved June 2021).
109 The index events for each were time of anti-diabetes medication prescription

110

111 **The study population at low-risk for bacterial enteric infection**

112 Two thiazolidinediones are available in the United States, pioglitazone and rosiglitazone.
113 Accordingly, all persons ≥ 18 years of age between January 2017 and January 2022 who within
114 1 month after a medical encounter for the diagnosis of type 2 diabetes mellitus were prescribed
115 thiazolidinediones (pioglitazone or rosiglitazone) or non-thiazolidinediones anti-diabetes
116 medications (Glucagon-like peptide-1 (GLP-1) analogues, insulin, metformin, sulfonylureas,
117 alpha glucosidase inhibitors, DPP-4 inhibitors, SGLT2 inhibitors), and had no prior history of
118 bacterial enteric infection before index event (prescription of anti-diabetes medication) were
119 included. The study population was then divided into two cohorts: (1) thiazolidinedione-users at
120 low risk and (2) non-thiazolidinedione users at low risk. Troglitazone users were excluded from
121 the study as the medication is not available in the US due to its hepatotoxicity. In the non-
122 thiazolidinedione cohort, persons with thiazolidinedione prescription were excluded from the
123 non-thiazolidinedione cohort.

124

125 **The study population at high-risk for bacterial enteric infection**

126 Two thiazolidinediones are available in the United States, pioglitazone and rosiglitazone.
127 Accordingly, all persons ≥ 18 years of age between January 2017 and January 2022 who within
128 1 month after a medical encounter for the diagnosis of type 2 diabetes mellitus were prescribed
129 thiazolidinediones (pioglitazone or rosiglitazone) or non-thiazolidinediones anti-diabetes
130 medications, and had prior history of bacterial enteric infection before index event (prescription

131 of anti-diabetes medication) were included. The study population was then divided into two
132 cohorts: (1) thiazolidinedione-users at high risk and (2) non-thiazolidinedione users at high risk.
133 Troglitazone users were excluded from the study as the medication is not available in the US
134 due to its hepatotoxicity. In the non-thiazolidinedione cohort, persons with thiazolidinedione
135 prescription were excluded from the non-thiazolidinedione cohort.

136

137 **Statistical analysis**

138 For each study cohort, the thiazolidinedione users and non-thiazolidinedione users were
139 propensity score matched (1:1 using nearest neighbor greedy matching with a caliper of 0.25
140 times the standard deviation) on covariates that are potential risk factors for bacterial enteric
141 infection including diabetes severity, such as age, sex, race, ethnicity, overweight and obesity,
142 lifestyle problems, ischemic heart disease, liver disease, kidney disease, lung disease,
143 hypertension, hyperlipidemia, cerebrovascular disease, atherosclerosis, other peripheral
144 vascular disease, tobacco use, alcohol use, human immunodeficiency virus (HIV), organ
145 transplant, use of immunosuppressants, use of chemotherapeutics, and Hemoglobin A1C
146 levels.

147

148 The outcome bacterial enteric infection that occurred in the 6-month time window after the index
149 event (prescription of medication) were compared between the matched medication groups. The
150 status of bacterial enteric infection was defined by ICD-10 A00-A05 (A00: Cholera, A01: Typhoid
151 and paratyphoid fevers, A02: Other salmonella infections, A03: Shigellosis, A04: Other bacterial
152 intestinal infections, A05: Other bacterial foodborne intoxications, not elsewhere classified). As
153 counts of bacterial enteric infection were low in the cohort, risk for an individual bacterial species
154 (i.e. *Salmonella sp*, *Enterohemorrhagic E coli*) precluded statistical analysis (most counts were
155 less than 10, therefore were rounded to 10 by TriNetX) and was not performed. Only a
156 composite outcome was investigated.

157

158 Several subgroup analyses were performed to assess the robustness of our results and
159 possible bias. First, outcomes were examined when stratified by sex and age. Second, given
160 diabetes medications are often prescribed in combination, it was necessary to evaluate whether
161 other medications commonly administered alongside thiazolidinediones could confound
162 observed effects. However, thiazolidinediones are rarely used for the management of T2DM
163 because of weight gain, pedal edema, and heart failure exacerbation, leading to their
164 classification as a third line option. Accordingly, thiazolidinediones were compared with another
165 third-line anti-diabetes medication, dipeptidyl peptidase-4 inhibitors (DPP-4) inhibitors. Age and
166 sex stratified analysis were not performed between thiazolidinediones and DPP-4 inhibitors as
167 subgroups often had less than 10 persons with the desired outcome. TriNetX to maintain
168 deidentification does not provide actual counts when below 10, which precludes accurate
169 statistical analysis. All statistical analysis were performed with the TriNetX Advanced Analytics
170 Platform. The TriNetX platform calculates RRs and associated confidence interval (CI) using R's
171 Survival package, version 3.2-3, with proportional hazard assumption tested using the
172 generalized Schoenfeld approach. Statistical significance was set a 2-sided P value of <0.05.

173

174 **Results:**

175

176 **Association of thiazolidinedione with risk of bacterial enteric infection in patients at low**
177 **risk**

178

179 The study population consisted of 85,917 and 2,154,426 persons with T2DM who between
180 1/2017-1/2022 were prescribed thiazolidinedione or non-thiazolidinedione anti-diabetes
181 medications, respectively, and had no prior history of bacterial enteric infection. Persons on
182 thiazolidinediones compared to non-thiazolidinedione were more likely to be older, male, white,
183 and had higher prevalence of overweight and obesity, chronic kidney disease, and Hgb A1C
184 levels greater than 9 (**Table 1**).

185

186 After 1:1 propensity matching, demographic and clinical characteristics were balanced (85,916
187 in each cohort, 63.2 years of age, 42.9% Female, 12.8% Black, 67.7% White, 14.3% Hispanic)
188 (**Table 1**). Matched cohorts were followed for 6 months after the index event. Compared to anti-
189 diabetes non-thiazolidinedione medications, thiazolidinedione was associated with a lower risk
190 of incident bacterial enteric infection among those at low-risk (0.03% vs 0.06%; RR 0.51, 95%
191 CI 0.32, 0.82). An association of lower risk for bacterial enteric infection was observed across
192 age and sex, however only among those >65 years were findings statistically significant (0.02%
193 vs 0.05%; RR 0.44, 95% CI 0.23,0.88) (**Figure 1**).

194
195 **Association of thiazolidinedione with risk of bacterial enteric infection in patients at high**
196 **risk**

197
198 The study population consisted of 1,975 and 57,963 persons with T2DM who between 1/2017-
199 1/2022 were prescribed thiazolidinedione or non-thiazolidinedione anti-diabetes medications,
200 respectively, and had prior history of bacterial enteric infection. Persons on thiazolidinediones
201 were more likely to be Hispanic and White, and had higher prevalence of overweight and
202 obesity, hypertension, hyperlipidemia, and Hb1C levels greater than 9.

203
204 After 1:1 propensity matching, demographic and clinical characteristics were balanced (1,974 in
205 each cohort, 63.0 years of age, 44.1% Female, 16.9% Black, 65.4% White, 20.8% Hispanic)
206 (**Table 1**). Matched cohorts were followed for 6 months after the index event. Compared to anti-
207 diabetes non-thiazolidinedione medications, thiazolidinedione was associated with a lower risk
208 of incident bacterial enteric infection among those at high risk (17.6% vs 22.5%; RR 0.78, 95%
209 CI 0.69,0.88). An association of lower risk for bacterial enteric infection was observed across all
210 sex and age subgroups (**Figure 2**).

211
212 **Association of thiazolidinedione compared to DPP-4 inhibitors with risk of bacterial**
213 **enteric infection in patients at low and high risk (sensitivity analysis)**
214

215 In the matched cohorts, thiazolidinedione use compared to those on DPP-4 inhibitors in patients
216 with T2DM was associated with a lower risk of bacterial enteric infection in those at high-risk
217 (RR 0.82, 95% CI 0.72,0.93) and not those at low-risk (RR 0.96, 95% CI 0.56, 1.65) (**Figure 3**).

218

219

220 **Discussion**

221 Our analysis identified a significant association between thiazolidinedione use and a reduced
222 risk of bacterial enteric infections in T2DM patients, consistent with findings from animal models.
223 This protective effect was observed in both low- and high-risk populations, with notable
224 reductions in infection across various age and sex subgroups, particularly in high-risk individuals
225 with a history of prior infections. The reduced risk seen when comparing thiazolidinediones to
226 third-line diabetes medications (DPP-4 inhibitors) further supports the hypothesis that
227 modulating PPAR- γ signaling mitigate bacterial enteric infections, especially in high-risk
228 situations—for example, protracted antibiotic use during hospitalization, international travel to
229 high incidence locales, or outbreaks in nursing homes and chronic care facilities.

230

231 Thiazolidinediones are typically used as a third-line medications when other anti-diabetes
232 medications have proven ineffective or when insurance limitations restrict alternative options
233 [12]. Consequently, thiazolidinedione users often represent a population with more severe or
234 poorly controlled diabetes, characterized by frequent healthcare encounters and lower
235 socioeconomic status [17-18]. These factors are associated with an increased risk of bacterial
236 enteric infection, suggesting the protective effect of thiazolidinediones may be greater than what
237 this analysis indicates [19-21].

238

239 Repurposing thiazolidinediones is not a novel concept. Initially, PPAR- γ was believed to
240 primarily function on adipose tissue, regulating insulin resistance, which led to the development

241 of thiazolidinediones for diabetes management [22]. However, investigators soon appreciated
242 the abundance of PPAR- γ in colonic epithelial cells and its involvement in colon cancer [23,24].
243 Subsequently, PPAR- γ signaling was shown to reduce colonic inflammation, prompting the
244 exploration of thiazolidinediones for inflammatory bowel disease [25]. Promising results were
245 observed in mouse models and clinical trials [25-27]. Despite these benefits, concerns over
246 toxicities, such as weight gain, fluid retention, and heart failure, have overshadowed the benefits
247 of thiazolidinediones. Therefore, while this study suggests thiazolidinediones may protect
248 against bacterial enteric infection, their repurposing for this indication is likely limited by their
249 associated risks.

250
251 Fortunately, there are alternative ways to increase PPAR- γ signaling. For instance, mesalamine
252 (5-ASA), a PPAR- γ agonist widely used for treating mild to moderate ulcerative colitis, may offer
253 a safer alternative. Studies suggest that 5-ASA prevents the expansion of colitogenic bacteria
254 such as *Escherichia coli* [10], indicating its potential role in preventing bacterial enteric infection
255 in high-risk individuals.

256
257 Dietary modifications may also enhance PPAR- γ signaling. A high-fiber diet can increase
258 butyrate levels, which, in turn, activate PPAR- γ . However, this depends on the presence of a gut
259 microbiota capable of butyrate production. Unsaturated fatty acids, found in dairy and meat
260 products, are natural PPAR- γ ligands and may also promote colonic health, although achieving
261 sufficient intraluminal concentrations *in vivo* remains controversial. Small animal studies have
262 demonstrated possible benefits from such dietary interventions [28,29].

263
264 One hypothesis behind the protective effects of PPAR- γ activation is its ability to maintain an
265 anaerobic environment in the gut, which helps prevent bacterial enteric infections. However, this
266 mechanism does not directly explain why thiazolidinediones may also protect against

267 *Clostridioides difficile*, an obligate anaerobe. It is possible that PPAR- γ signaling supports the
268 growth of beneficial anaerobes such as *Clostridium scindens* or *Blautia producta*, which inhibit
269 *C. difficile* through the production of secondary bile acids and lantibiotics, respectively [30,31].
270 Further, PPAR- γ activity in macrophages, which has been shown to ameliorate colonic
271 inflammation, may also contribute to this protective effect. Given that thiazolidinediones are
272 primarily absorbed in the small intestine and may not directly reach the colon, this macrophage-
273 mediated mechanism merits further investigation [10].

274

275 **Limitations**

276 There are limitations that bear consideration when interpreting the results of this study. Residual
277 confounding, particularly diabetes severity, may impact the findings. Although we controlled for
278 factors like ischemic heart disease, peripheral vascular disease, chronic kidney disease, and
279 HbA1C levels, fully characterizing the severity of diabetes remains a challenge. Further,
280 medication adherence cannot be confirmed based on electronic health records. However, our
281 inclusion of individuals with thiazolidinedione or other anti-diabetes prescriptions following a
282 healthcare encounter for T2DM suggests active management of the disease. Limited sample
283 sizes precluded an analysis of dose-dependent effects and we could not assess the duration of
284 thiazolidinedione use required for a protective effect. Further, since T2DM is often managed with
285 a combination of medications, it is possible that other medications commonly used alongside
286 thiazolidinediones contributed to the observed protective effect. To address this, we conducted a
287 direct comparison with DPP-4 inhibitors, which showed a decreased risk of bacterial enteric
288 infection in high-risk individuals. Lastly, the severity of enteric infections was not captured in this
289 study, so it remains unknown whether thiazolidinediones can reduce disease severity.

290

291 **Conclusion**

292 Bacterial enteric infections remain a significant public health concern, with acute gastroenteritis
293 causing an estimated 179 million outpatient visits and nearly 500,000 hospitalizations annually
294 [32-34]. Current antimicrobial treatments are often inadequate, as antibiotics can prolong
295 symptoms, increase bacterial shedding, and lead to recurrence [14-16]. Given the limitations of
296 existing treatments, preserving beneficial intestinal microbes with alternative therapies that
297 minimize collateral damage to the microbiome is a key consideration. In this context PPAR- γ
298 agonists may offer a promising alternative.

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318 **References**

- 319 1. Caballero-Flores G, Pickard JM, Núñez G. Microbiota-mediated colonization resistance:
320 mechanisms and regulation. *Nat Rev Microbiol.* 2023 Jun;21(6):347-360. doi:
321 10.1038/s41579-022-00833-7. Epub 2022 Dec 20. PMID: 36539611; PMCID:
322 PMC10249723.
- 323 2. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal
324 pathogens. *Nat Rev Immunol.* 2013 Nov;13(11):790-801. doi: 10.1038/nri3535. Epub
325 2013 Oct 7. PMID: 24096337; PMCID: PMC4194195.
- 326 3. Petri WA Jr, Miller M, Binder HJ, Levine MM, Dillingham R, Guerrant RL. Enteric
327 infections, diarrhea, and their impact on function and development. *J Clin Invest.* 2008
328 Apr;118(4):1277-90. doi: 10.1172/JCI34005. PMID: 18382740; PMCID: PMC2276781.
- 329 4. Byndloss MX, Olsan EE, Rivera-Chávez F, Tiffany CR, Cevallos SA, Lokken KL, Torres
330 TP, Byndloss AJ, Faber F, Gao Y, Litvak Y, Lopez CA, Xu G, Napoli E, Giulivi C, Tsois
331 RM, Revzin A, Lebrilla CB, Bäumlér AJ. Microbiota-activated PPAR- γ signaling inhibits
332 dysbiotic Enterobacteriaceae expansion. *Science.* 2017 Aug 11;357(6351):570-575. doi:
333 10.1126/science.aam9949. PMID: 28798125; PMCID: PMC5642957.
- 334 5. Litvak Y, Byndloss MX, Bäumlér AJ. Colonocyte metabolism shapes the gut microbiota.
335 *Science.* 2018 Nov 30;362(6418):eaat9076. doi: 10.1126/science.aat9076. PMID:
336 30498100; PMCID: PMC6296223.
- 337 6. Yoo W, Zieba JK, Foegeding NJ, Torres TP, Shelton CD, Shealy NG, Byndloss AJ,
338 Cevallos SA, Gertz E, Tiffany CR, Thomas JD, Litvak Y, Nguyen H, Olsan EE, Bennett
339 BJ, Rathmell JC, Major AS, Bäumlér AJ, Byndloss MX. High-fat diet-induced colonocyte
340 dysfunction escalates microbiota-derived trimethylamine *N*-oxide. *Science.* 2021 Aug
341 13;373(6556):813-818. doi: 10.1126/science.aba3683. PMID: 34385401; PMCID:
342 PMC8506909.
- 343 7. Lee JY, Cevallos SA, Byndloss MX, Tiffany CR, Olsan EE, Butler BP, Young BM,
344 Rogers AWL, Nguyen H, Kim K, Choi SW, Bae E, Lee JH, Min UG, Lee DC, Bäumlér
345 AJ. High-Fat Diet and Antibiotics Cooperatively Impair Mitochondrial Bioenergetics to
346 Trigger Dysbiosis that Exacerbates Pre-inflammatory Bowel Disease. *Cell Host Microbe.*
347 2020 Aug 12;28(2):273-284.e6. doi: 10.1016/j.chom.2020.06.001. Epub 2020 Jul 14.
348 PMID: 32668218; PMCID: PMC7429289.
- 349 8. Rivera-Chávez F, Zhang LF, Faber F, Lopez CA, Byndloss MX, Olsan EE, Xu G,
350 Velazquez EM, Lebrilla CB, Winter SE, Bäumlér AJ. Depletion of Butyrate-Producing
351 Clostridia from the Gut Microbiota Drives an Aerobic Luminal Expansion of Salmonella.
352 *Cell Host Microbe.* 2016 Apr 13;19(4):443-54. doi: 10.1016/j.chom.2016.03.004. PMID:
353 27078066; PMCID: PMC4832419.
- 354 9. Shelton CD, Sing E, Mo J, Shealy NG, Yoo W, Thomas J, Fitz GN, Castro PR, Hickman
355 TT, Torres TP, Foegeding NJ, Zieba JK, Calcutt MW, Codreanu SG, Sherrod SD,
356 McLean JA, Peck SH, Yang F, Markham NO, Liu M, Byndloss MX. An early-life
357 microbiota metabolite protects against obesity by regulating intestinal lipid metabolism.
358 *Cell Host Microbe.* 2023 Oct 11;31(10):1604-1619.e10. doi:
359 10.1016/j.chom.2023.09.002. Epub 2023 Oct 3. PMID: 37794592; PMCID:
360 PMC10593428.
- 361 10. Savage HP, Bays DJ, Tiffany CR, Gonzalez MAF, Bejarano EJ, Carvalho TP, Luo Z,
362 Masson HLP, Nguyen H, Santos RL, Reagan KL, Thompson GR, Bäumlér AJ. Epithelial
363 hypoxia maintains colonization resistance against *Candida albicans*. *Cell Host Microbe.*
364 2024 Jul 10;32(7):1103-1113.e6. doi: 10.1016/j.chom.2024.05.008. Epub 2024 Jun 4.
365 PMID: 38838675; PMCID: PMC11239274.
- 366 11. Cevallos SA, Lee JY, Velazquez EM, Foegeding NJ, Shelton CD, Tiffany CR, Parry BH,
367 Stull-Lane AR, Olsan EE, Savage HP, Nguyen H, Ghanaat SS, Byndloss AJ, Agu IO,
368 Tsois RM, Byndloss MX, Bäumlér AJ. 5-Aminosalicylic Acid Ameliorates Colitis and

- 369 Checks Dysbiotic *Escherichia coli* Expansion by Activating PPAR- γ Signaling in the
370 Intestinal Epithelium. *mBio*. 2021 Jan 19;12(1):e03227-20. doi: 10.1128/mBio.03227-20.
371 PMID: 33468700; PMCID: PMC7845635.
- 372 12. Yki-Järvinen H. Thiazolidinediones. *N Engl J Med*. 2004 Sep 9;351(11):1106-18. doi:
373 10.1056/NEJMra041001. PMID: 15356308.
- 374 13. American Diabetes Association Professional Practice Committee. 9. Pharmacologic
375 Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.
376 *Diabetes Care*. 2022 Jan 1;45(Suppl 1):S125-S143. doi: 10.2337/dc22-S009. PMID:
377 34964831.
- 378 14. Shane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Kotloff K, Langley JM, Wanke C,
379 Warren CA, Cheng AC, Cantey J, Pickering LK. 2017 Infectious Diseases Society of
380 America Clinical Practice Guidelines for the Diagnosis and Management of Infectious
381 Diarrhea. *Clin Infect Dis*. 2017 Nov 29;65(12):e45-e80. doi: 10.1093/cid/cix669. PMID:
382 29053792; PMCID: PMC5850553.
- 383 15. Humphries RM, Linscott AJ. Practical Guidance for Clinical Microbiology Laboratories:
384 Diagnosis of Bacterial Gastroenteritis. *Clin Microbiol Rev*. 2015 Jan;28(1):3-31. doi:
385 10.1128/CMR.00073-14. PMID: 25567220; PMCID: PMC4284301.
- 386 16. Peniche AG, Savidge TC, Dann SM. Recent insights into *Clostridium difficile*
387 pathogenesis. *Curr Opin Infect Dis*. 2013 Oct;26(5):447-53. doi:
388 10.1097/01.qco.0000433318.82618.c6. PMID: 23982235.
- 389 17. Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM. Epidemiology, Clinical
390 Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial
391 Management of Invasive *Salmonella* Infections. *Clin Microbiol Rev*. 2015 Oct;28(4):901-
392 37. doi: 10.1128/CMR.00002-15. PMID: 26180063; PMCID: PMC4503790.
- 393 18. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P,
394 Chamailard M, Desreumaux P. PPAR γ as a new therapeutic target in
395 inflammatory bowel diseases. *Gut*. 2006 Sep;55(9):1341-9. doi:
396 10.1136/gut.2006.093484. PMID: 16905700; PMCID: PMC1860011.
- 397 19. Arnold SV, Inzucchi SE, Echouffo-Tcheugui JB, Tang F, Lam CSP, Sperling LS,
398 Kosiborod M. Understanding Contemporary Use of Thiazolidinediones. *Circ Heart Fail*.
399 2019 Jun;12(6):e005855. doi: 10.1161/CIRCHEARTFAILURE.118.005855. PMID:
400 31129998.
- 401 20. Qato DM, Trivedi AN, Mor V, Dore DD. Disparities in Discontinuing Rosiglitazone
402 Following the 2007 FDA Safety Alert. *Med Care*. 2016 Apr;54(4):406-13. doi:
403 10.1097/MLR.0000000000000502. PMID: 26978569; PMCID: PMC4807625.
- 404 21. Chang M, Groseclose SL, Zaidi AA, Braden CR. An ecological analysis of
405 sociodemographic factors associated with the incidence of salmonellosis, shigellosis,
406 and *E. coli* O157:H7 infections in US counties. *Epidemiol Infect*. 2009 Jun;137(6):810-
407 20. doi: 10.1017/S0950268808001477. Epub 2008 Oct 24. PMID: 18947443.
- 408 22. Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, Braverman S, Tengeler
409 AC, Barak O, Elazar M, Ben-Zeev R, Lehavi-Regev D, Katz MN, Pevsner-Fischer M,
410 Gertler A, Halpern Z, Harmelin A, Amar S, Serradas P, Grosfeld A, Shapiro H, Geiger
411 B, Elinav E. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric
412 infection. *Science*. 2018 Mar 23;359(6382):1376-1383. doi: 10.1126/science.aar3318.
413 Epub 2018 Mar 8. PMID: 29519916.
- 414 23. Bobo LD, Dubberke ER. Recognition and prevention of hospital-associated enteric
415 infections in the intensive care unit. *Crit Care Med*. 2010 Aug;38(8 Suppl):S324-34. doi:
416 10.1097/CCM.0b013e3181e69f05. PMID: 20647790; PMCID: PMC3657464.
- 417 24. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P,
418 Chamailard M, Desreumaux P. PPAR γ as a new therapeutic target in

- 419 inflammatory bowel diseases. *Gut*. 2006 Sep;55(9):1341-9. doi:
420 10.1136/gut.2006.093484. PMID: 16905700; PMCID: PMC1860011.
- 421 25. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans
422 RM. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. *Nat*
423 *Med*. 1998 Sep;4(9):1058-61. doi: 10.1038/2042. PMID: 9734400.
- 424 26. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB,
425 Singer S, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes
426 in colon cancer through PPARgamma. *Nat Med*. 1998 Sep;4(9):1046-52. doi:
427 10.1038/2030. PMID: 9734398.
- 428 27. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S,
429 Lazar MA, Wu GD. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the
430 epithelial inflammatory response. *J Clin Invest*. 1999 Aug;104(4):383-9. doi:
431 10.1172/JCI7145. PMID: 10449430; PMCID: PMC408529.
- 432 28. Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie
433 EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD. An open-label trial of the PPAR-
434 gamma ligand rosiglitazone for active ulcerative colitis. *Am J Gastroenterol*. 2001
435 Dec;96(12):3323-8. doi: 10.1111/j.1572-0241.2001.05333.x. PMID: 11774944.
- 436 29. Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B,
437 Present DH, Chuai S, Ellenberg JH, Nessel L, Wu GD; Rosiglitazone for Ulcerative
438 Colitis Study Group. Rosiglitazone for active ulcerative colitis: a randomized placebo-
439 controlled trial. *Gastroenterology*. 2008 Mar;134(3):688-95. doi:
440 10.1053/j.gastro.2007.12.012. Epub 2007 Dec 7. PMID: 18325386; PMCID:
441 PMC2276587.
- 442 30. Hontecillas R, Wannemeulher MJ, Zimmerman DR, Hutto DL, Wilson JH, Ahn DU,
443 Bassaganya-Riera J. Nutritional regulation of porcine bacterial-induced colitis by
444 conjugated linoleic acid. *J Nutr*. 2002 Jul;132(7):2019-27. doi: 10.1093/jn/132.7.2019.
445 PMID: 12097686.
- 446 31. Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, Gonzalez F,
447 Rohrer J, Benninghoff AU, Hontecillas R. Activation of PPAR gamma and delta by
448 conjugated linoleic acid mediates protection from experimental inflammatory bowel
449 disease. *Gastroenterology*. 2004 Sep;127(3):777-91. doi: 10.1053/j.gastro.2004.06.049.
450 PMID: 15362034.
- 451 32. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H,
452 Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C,
453 Cross JR, Toussaint NC, Xavier JB, Pamer EG. Precision microbiome reconstitution
454 restores bile acid mediated resistance to *Clostridium difficile*. *Nature*. 2015 Jan
455 8;517(7533):205-8. doi: 10.1038/nature13828. Epub 2014 Oct 22. PMID: 25337874;
456 PMCID: PMC4354891.
- 457 33. Kim SG, Becattini S, Moody TU, Shliha PV, Littmann ER, Seok R, Gjonbalaj M, Eaton
458 V, Fontana E, Amoretti L, Wright R, Caballero S, Wang ZX, Jung HJ, Morjaria SM,
459 Leiner IM, Qin W, Ramos RJJF, Cross JR, Narushima S, Honda K, Peled JU,
460 Hendrickson RC, Taur Y, van den Brink MRM, Pamer EG. Microbiota-derived lantibiotic
461 restores resistance against vancomycin-resistant *Enterococcus*. *Nature*. 2019
462 Aug;572(7771):665-669. doi: 10.1038/s41586-019-1501-z. Epub 2019 Aug 21. PMID:
463 31435014; PMCID: PMC6717508.
- 464 34. Scallan E, Griffin PM, Angulo FJ, Tauxe RV, Hoekstra RM. Foodborne illness acquired
465 in the United States--unspecified agents. *Emerg Infect Dis*. 2011 Jan;17(1):16-22. doi:
466 10.3201/eid1701.091101p2. PMID: 21192849; PMCID: PMC3204615.
- 467 35. Mounts AW, Holman RC, Clarke MJ, Bresee JS, Glass RI. Trends in hospitalizations
468 associated with gastroenteritis among adults in the United States, 1979-1995. *Epidemiol*

- 469 Infect. 1999 Aug;123(1):1-8. doi: 10.1017/s0950268899002587. PMID: 10487635;
470 PMCID: PMC2810722.
- 471 36. Kendall ME, Crim S, Fullerton K, Han PV, Cronquist AB, Shiferaw B, Ingram LA, Rounds
472 J, Mintz ED, Mahon BE. Travel-associated enteric infections diagnosed after return to
473 the United States, Foodborne Diseases Active Surveillance Network (FoodNet), 2004-
474 2009. Clin Infect Dis. 2012 Jun;54 Suppl 5:S480-7. doi: 10.1093/cid/cis052. PMID:
475 22572673.
- 476
- 477

478 **AUTHOR CONTRIBUTIONS**

479 MB conceptualized the project, designed the analysis, processed the data, and analyzed the
480 results. DCK assisted with data acquisition. MB wrote the manuscript, DCK, VN, and AZ
481 provided critical intellectual input. AZ supervised the study and is ultimately responsible for its
482 content.

483

484

485 **ACKNOWLEDGMENTS**

486 MB is supported by T32 AI007036. DCK is supported by the Clinical and Translational Science
487 Collaborative of Northern Ohio which is funded by the National Center for Advancing
488 Translational Sciences (NCATS) of the National Institutes of Health, UM1TR004528. AZ is
489 supported by NIH R01AZ is supported by NIH R01 EB030134, R01 AI163483, U01 CA265719,
490 and VA Merit BLR&D Award I01 BX005707. All authors receive institutional support from NIH
491 P30 DK120515, P30 DK063491, and UL1 TR001442.

492

493 **CONFLICT OF INTEREST**

494 AZ is a co-founder and acting CMO of Endure Biotherapeutics. He holds equity in the company.

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513 Table 1: Characteristics of the thiazolidinedione cohort and the non-thiazolidinedione anti-
514 diabetes medication cohort for the study population at low risk for bacterial enteric infection

Characteristics	Before matching			After matching		
	TZD users	Non-TZD users	Std diff	TZD users	Non-TZD users	Std diff.
Total No.	85,917	2,154,436		85,916	85,916	
Age, mean, y	63.2 ± 12.3	61.4 ± 14.5	0.13	63.2 ± 12.3	63.4 ± 12.8	0.014
Sex, %						
Male	54.9	49.0	0.117	54.9	55.5	0.013
Female	42.9	46.9	0.082	42.9	42.3	0.012
Ethnicity, %						
Hispanic/Latino	14.3	9.3	0.156	14.3	13.6	0.021
Not Hispanic/Latino	64.2	62.3	0.040	64.2	65.1	0.019
Unknown	21.5	28.4	0.161	21.5	21.3	0.005
Race,%						
African American/Black	12.8	18.0	0.144	12.8	12.8	0.001
Asian	5.1	4.4	0.034	5.1	5.1	0.001
White	67.7	59.9	0.164	67.7	68.1	0.008
American Indian or Alaska Native	0.3	0.3	0.002	0.3	0.3	0.002
Native Hawaiian or other Pacific Islander	0.4	0.6	0.033	0.4	0.3	0.007
Other Race	3.4	3.4	0.002	3.4	3.3	0.009
Unknown	10.3	13.5	0.100	10.3	10.1	0.005
Problems related to lifestyle	4.5	4.0	0.023	4.5	4.1	0.024
Tobacco Use	10.0	10.7	0.022	10.0	9.1	0.030
Alcohol Use Disorder	2.1	2.8	0.049	2.1	1.8	0.017
Comorbidities, %						
Overweight & Obesity	31.0	25.0	0.134	31.0	30.1	0.019
BMI 19.9 or less	0.3	0.5	0.027	0.3	0.3	0.008
BMI 20-29	4.8	4.0	0.042	4.8	4.4	0.019
BMI 30-39	12.3	9.2	0.100	12.3	11.9	0.013
BMI 40 or greater	7.2	6.3	0.037	7.2	7.0	0.011
Hypertension	64.0	51.6	0.254	64.0	63.5	0.011
Hyperlipidemia	48.4	35.5	0.264	48.4	47.7	0.015
Chronic respiratory disease	17.0	17.1	0.004	17.0	16.3	0.018
Liver Disease	10.2	8.6	0.057	10.2	9.5	0.025
Chronic Kidney Disease	14.0	12.6	0.040	14.0	13.2	0.023
CKD Stage 1	0.8	0.5	0.031	0.8	0.7	0.012
CKD Stage 2 (mild)	2.5	1.8	0.048	2.5	2.2	0.018
CKD Stage 3 (moderate)	12.3	9.2	0.083	9.1	8.7	0.016
CKD Stage 4 (severe)	1.9	2.2	0.016	1.9	1.8	0.011
CKD Stage 5	0.5	1.0	0.054	0.5	0.5	0.003
End stage renal disease	1.2	2.7	0.106	1.2	1.2	0.006
Ischemic heart disease	17.0	18.4	0.035	17.0	16.3	0.019
Cerebrovascular Disease	8.7	9.1	0.011	8.7	8.1	0.023
Atherosclerosis	4.5	4.1	0.001	4.5	4.1	0.020
Other peripheral vascular disease	5.7	5.2	0.022	5.7	5.1	0.026

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

	HIV	0.6	0.5	0.012	0.6	0.5	0.009
	Organ Transplant	0.9	1.6	0.060	0.9	0.9	0.006
Medications, %							
	Immunosuppressants	3.2	3.5	0.017	3.2	3.0	0.012
	Chemotherapy	12.4	11.4	0.030	12.4	12.0	0.014
Labs, %							
Hemoglobin A1C							
	<9%	54.3	43.2	0.225	54.3	54.0	0.006
	≥9%	30.6	16.5	0.338	30.6	30.1	0.011

515 Abbreviations: TZD; thiazolidinedione, non-TZD; non-thiazolidinedione, std diff; Standard mean difference, y; years,
516 CKD; chronic kidney disease, HIV; Human Immunodeficiency Virus; BMI; body mass index

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532


533

534

535

536

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .



537
538 Figure 1: Risk of bacterial enteric infection in low-risk individuals (no prior history of
539 bacterial enteric infection); BEI, Bacterial Enteric Infection

540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558

559 Table 2: Characteristics of the thiazolidinedione cohort and the non-thiazolidinedione anti-
560 diabetes medication cohort for the study population at high-risk for bacterial enteric infection

Characteristics	Before matching			After matching		
	TZD users	Non-TZD users	Std diff.	TZD users	Non-TZD users	Std diff.
Total No.	1,975	57,963		1,974	1,974	
Age, mean, y	63.0 ± 12.7	62.6 ± 14.1	0.029	63.0 ± 12.7	63.1 ± 13.3	0.007
Sex, %						
Male	44.1	43.3	0.017	44.1	42.8	0.027
Female	54.3	52.9	0.029	54.3	55.1	0.017
Ethnicity, %						
Hispanic/Latino	20.9	12.3	0.233	20.8	20.8	0.001
Not Hispanic/Latino	65.7	66.3	0.013	65.7	64.5	0.026
Unknown	13.5	21.4	0.211	13.5	14.7	0.036
Race,%						
African American/Black	16.9	20.8	0.099	16.9	16.3	0.016
Asian	4.4	4.1	0.014	4.4	4.4	<0.001
White	65.4	57.7	0.158	65.4	65.8	0.009
American Indian or Alaska Native	0.5	0.4	0.020	0.5	0.5	<0.001
Native Hawaiian or other Pacific Islander	0.6	1.0	0.053	0.6	0.5	0.007
Other Race	3.4	3.3	0.011	3.4	3.2	0.011
Unknown	9.0	12.7	0.120	9.0	9.4	0.014
Lifestyle problem	8.6	7.6	0.036	8.6	7.4	0.041
Tobacco Use	16.2	18.2	0.053	16.2	14.4	0.049
Alcohol Use Disorder	5.3	6.9	0.067	5.3	4.4	0.040
Comorbidities, %						
Overweight & Obesity	45.9	38.6	0.147	45.8	43.4	0.049
BMI 19.9 or less	1.8	2.0	0.011	1.8	1.6	0.020
BMI 20-29	8.4	8.4	0.001	8.4	7.0	0.049
BMI 30-39	17.5	15.2	0.061	17.5	16.0	0.039
BMI 40 or greater	12.7	10.5	0.067	12.6	11.6	0.031
Hypertension	79.8	71.5	0.195	79.8	77.1	0.067
Hyperlipidemia	67.4	54.7	0.263	67.4	64.9	0.051
Chronic respiratory disease	29.6	31.9	0.050	29.6	27.7	0.043
Liver Disease	24.4	21.8	0.061	24.2	22.2	0.052
Chronic Kidney Disease	28.7	32.5	0.084	28.6	27.4	0.027
CKD Stage 1	2.0	1.5	0.036	1.9	2.3	0.028
CKD Stage 2 (mild)	5.7	5.1	0.026	5.7	6.3	0.026
CKD Stage 3 (moderate)	19.3	18.2	0.029	19.3	18.2	0.027
CKD Stage 4 (severe)	5.4	8.6	0.125	5.4	5.1	0.014
CKD Stage 5	1.7	5.0	0.184	1.7	1.6	0.012
End stage renal disease	4.4	10.9	0.248	4.4	4.0	0.020
Ischemic heart disease	28.7	33.9	0.113	28.7	26.2	0.055
Cerebrovascular Disease	17.0	18.9	0.050	16.9	14.6	0.064
Atherosclerosis	10.9	12.2	0.043	10.9	9.2	0.056
Other peripheral vascular disease	11.6	12.8	0.037	11.6	10.0	0.051
HIV	1.4	1.3	0.007	1.4	1.3	0.009
Organ Transplant	3.7	8.0	0.184	3.7	4.0	0.013
Medications						
Immunosuppressants	8.2	11.7	0.116	8.2	7.0	0.044
Chemotherapy	24.8	25.6	0.020	24.8	22.7	0.049
Labs						
Hemoglobin A1C						

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

<9%	69.8	61.6	0.173	69.8	69.1	0.014
≥9%	43.0	24.5	0.400	43.0	43.2	0.003

561 Abbreviations: TZD; thiazolidinedione, non-TZD; non-thiazolidinedione, std diff; Standard mean difference, y; years,
562 CKD; chronic kidney disease, HIV; Human Immunodeficiency Virus; BMI; body mass index

563

564

565

566

567

568

569

570

571

572

573

574

575

576


577

578

579


580

581



582
583 Figure 2: Risk of bacterial enteric infection in high-risk individuals (prior history of bacterial
584 enteric infection); BEI, Bacterial Enteric Infection

585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604



605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629

Figure 3: Risk of bacterial enteric infection in thiazolidine users compared to DPP-4 inhibitors with T2DM in low-risk (no prior history of bacterial enteric infection) and high-risk (prior history of bacterial enteric infection); BEI, Bacterial Enteric Infection, T2DM, Type 2 Diabetes Mellitus

630

631 Supplementary Table 1: Definition of variables

Variable	Definition
Thiazolidinediones	ATC: 84108,33738
Non-thiazolidinedione	ATC: A10A, A10BA, A10VV, A10VF, A10BH, A10BH, A10BJ, A10BK, A10BX
DPP-4 inhibitors	A10BH
Type 2 Diabetes Mellitus	ICD 10: E11
Age	Time of index
Sex	male or female
Race	Black or African American (2054-5), White (2106-3), Asian (2028-9), American Indian or Alaska native (1002-5), Native Hawaiian or Other Pacific Islander (2076-81), Other Race, Unknown
Ethnicity	Hispanic or Latino (2135-2), Not Hispanic or Latino (2186-5), Unknown
Lifestyle Problems	ICD10: Z72
Tobacco Use	ICD 10: F17
Alcohol Use	ICD 10: F10
Overweight & Obesity	ICD 10: E66
BMI	ICD: Z68.1 - Z68.4
Hypertension	ICD 10: I10
Hyperlipidemia	ICD10: E78.5
Chronic respiratory disease	ICD 10: J40-J4A
Chronic Kidney Disease	ICD 10: N18, N18.1-N18.6
Ischemic Heart Disease	ICD10: I20-I25
Cerebrovascular Disease	ICD 10: I60-I69
Atherosclerosis	ICD 10: I70
Other peripheral vascular disease	ICD 10: I73
Human immunodeficiency virus	ICD10: B20
Organ Transplant	ICD 10: Z94
Immunosuppressants	ATC: L04
Chemotherapy	ATC: L
HgbA1C	TNX Curated: 9037

632